Central Nervous System Clinical Trials

150 recruitingLast updated: April 21, 2026

There are 150 actively recruiting central nervous system clinical trials across 35 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1. Top locations include New York, New York, United States, Beijing, Beijing Municipality, China, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Central Nervous System Trials at a Glance

150 actively recruiting trials for central nervous system are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Phase 2 with 46 trials, with the heaviest enrollment activity in New York, Beijing, and Houston. Lead sponsors running central nervous system studies include M.D. Anderson Cancer Center, Children's Oncology Group, and Mayo Clinic.

Browse central nervous system trials by phase

About Central Nervous System Clinical Trials

Looking for clinical trials for Central Nervous System? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Central Nervous System trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Central Nervous System clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 150 trials

Recruiting
Phase 1

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
National Cancer Institute (NCI)47 enrolled54 locationsNCT04609046
Recruiting

Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System

Multiple SclerosisCentral Nervous System Disease
National Institute of Allergy and Infectious Diseases (NIAID)2,400 enrolled1 locationNCT00794352
Recruiting

Natural History of Depression, Bipolar Disorder and Suicide Risk

Molecular Mechanisms of Pharmacological ActionDepressive SymptomsSuicide+17 more
National Institute of Mental Health (NIMH)500 enrolled1 locationNCT06462196
Recruiting
Phase 1Phase 2

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting

INfectious DIsease REgistry BIObank

Central Nervous System InfectionsBloodstream Infections
IRCCS San Raffaele10,000 enrolled1 locationNCT06418048
Recruiting
Phase 1Phase 2

A Study of Mirdametinib in People With Central Nervous System Tumors

GliomaCentral Nervous System Tumors
Memorial Sloan Kettering Cancer Center26 enrolled7 locationsNCT07539441
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled3 locationsNCT07326566
Recruiting
Phase 2

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Primary Central Nervous System Lymphoma (PCNSL)
Beijing Tongren Hospital43 enrolled1 locationNCT07523737
Recruiting
Phase 1Phase 2

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

MeningiomaRecurrent Diffuse Intrinsic Pontine GliomaHigh Grade Glioma+10 more
Nationwide Children's Hospital65 enrolled4 locationsNCT05278208
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Phase 1

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Germ Cell TumorChoroid Plexus CarcinomaCentral Nervous System Tumor+8 more
Seattle Children's Hospital90 enrolled1 locationNCT04185038
Recruiting
Phase 1Phase 2

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Not Applicable

Cancer Genetic Testing in Ethnic Populations

Breast CarcinomaHead and Neck CarcinomaMalignant Brain Neoplasm+8 more
Mayo Clinic1,800 enrolled2 locationsNCT04475640
Recruiting
Phase 1

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell CarcinomaMetastatic Melanoma+7 more
M.D. Anderson Cancer Center75 enrolled1 locationNCT03025256
Recruiting
Phase 3

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Mixed Phenotype Acute LeukemiaB Acute Lymphoblastic LeukemiaB Lymphoblastic Lymphoma+2 more
Children's Oncology Group5,951 enrolled230 locationsNCT03959085
Recruiting
Phase 3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

DementiaBrain DiseasesCentral Nervous System Diseases+6 more
Eli Lilly and Company1,500 enrolled141 locationsNCT05508789
Recruiting
Not Applicable

Mixed Reality and Virtual Reality Technology With Mirror Therapy for Stroke Rehabilitation

Central Nervous System DiseasesStrokeCerebrovascular Disorders
Chang Gung Memorial Hospital45 enrolled1 locationNCT05903235
Recruiting
Phase 1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Central Nervous System TumorGlioblastomaCNS Tumor+5 more
Sabine Mueller, MD, PhD208 enrolled6 locationsNCT04732065
Recruiting
Phase 2

ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse

Lymphoma Patients With High-risk of Central Nervous System Relapse
Second Affiliated Hospital, School of Medicine, Zhejiang University45 enrolled1 locationNCT07481669